Search

Displaying results 2051 - 2060 of 10000 in total
  1. Drug

    Rabies immune globulin, human

    go.drugbank.com/drugs/DB11603
    Approved

    IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced … Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory

    Products: HyperRAB Solution for Infiltration & Intramuscular Injection, Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze
  2. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    ), another tyrosine kinase inhibitor used as a first-line treatment for CML. … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML).

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Adenine

    go.drugbank.com/drugs/DB00173
    ApprovedInvestigationalNutraceutical

    A purine base and a fundamental unit of adenine nucleotides.

    Mixtures: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood, TERUFLEX Blood Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) for Collection of 450mL of Blood
  4. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor was approved by the FDA in June 2015 for intravenous application. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

  5. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    [L43967,L43972] It was subsequently granted full approval in March 2024.[L50306] In October 2024, it was approved in the EU for the same indication. [L52640] … Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide

  6. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).

  7. Drug

    Deserpidine

    go.drugbank.com/drugs/DB01089
    ApprovedWithdrawn

    Deserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure … and for the relief of psychotic behavior.

  8. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

  9. Drug

    Macitentan

    go.drugbank.com/drugs/DB08932
    ApprovedInvestigational

    A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024. … Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013.

    Categories: Endothelin A Receptor Antagonists, Antihypertensives for Pulmonary Arterial Hypertension
  10. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro. … Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition.

    Mixtures: Keloid Healer Synergy for treatment of keloidsCategories: Compounds used in a research, industrial, or household setting